Iovance Biotherapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frederick G. Vogt
- Full Time Employees
- 975
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 825 Industrial Road San Carlos CA United States of America 94070
- IPO Date
- Oct 15, 2010
- CIK
- 0001425205
- Website
- iovance.com
- Similar Companies
- Business
- Iovance Biotherapeutics, Inc. is a pioneering biotechnology firm focused on developing and commercializing cell therapies that leverage a patient's own immune system to combat cancer. Headquartered in San Carlos, California, the company specializes in tumor-infiltrating lymphocyte (TIL) technology, aiming to deliver personalized treatment options for various advanced solid tumor cancers. The company's lead product, AMTAGVI (lifileucel), received accelerated approval from the U.S. Food and Drug Administration (FDA) in February 2024 for adults with unresectable or metastatic melanoma who have undergone prior treatments. This marked a significant milestone as the first FDA-approved T-cell therapy for a solid tumor indication. Iovance's revenue model primarily revolves around the sale of its innovative therapies like AMTAGVI and its interleukin-2 product, Proleukin, which supports the AMTAGVI treatment regimen. The company generated approximately $250.43 million in revenue over the last twelve months, with a substantial increase driven by the commercial launch of AMTAGVI in 2024. Iovance continues to advance its robust clinical pipeline, investigating TIL therapy across multiple solid tumor types. Key ongoing clinical programs include further studies of lifileucel (Amtagvi) for advanced melanoma, including a Phase 3 trial (TILVANCE-301) in combination with pembrolizumab, and a registrational Phase 2 study (IOV-LUN-202) for advanced non-small cell lung cancer (NSCLC). Additionally, the pipeline features next-generation TIL therapies like IOV-4001, a PD-1 inactivated TIL therapy, and IOV-3001, a modified IL-2 analog, both in early to mid-stage development with anticipated clinical data in 2026. The company also plans an Investigational New Drug (IND) submission in early 2026 for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 TIL therapy, targeting solid tumors with high unmet needs. Iovance Biotherapeutics aims to be a global leader in TIL therapy, driven by its unique patient-specific cell therapy platform designed to recognize and attack diverse cancer cells. The company emphasizes innovation, patient-centricity, and a pioneering approach to transform cancer treatment, with a strong focus on expanding market reach into new territories such as the UK, EU, and Canada in 2025. Founded in 2007, Iovance was previously known as Lion Biotechnologies, Inc. before adopting its current name in 2017.
Company News
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP
Iovance: Buy Now Before Many Growth Catalysts Kick In
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Major Indexes Slide as Investors Digest Consumer Sentiment Data
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Why Iovance Biotherapeutics Stock Was on Fire Today
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
4 Biotech Stocks to Watch as Potential Takeover Targets
Squarepoint Ops LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA
Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)
108,050 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by VIRGINIA RETIREMENT SYSTEMS ET Al